BCAB — Bioatla Inc
NASDAQ · Healthcare · Biotechnology
$1.29
+$0.20 (+18.42%)
Bioatla Inc (BCAB) is a biotechnology company listed on NASDAQ. It is led by Jay M. Short Ph.D., based in 11085 Torreyana Road, San Diego, CA, United States, 92121, with about 41 employees. BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Net income was -$15.8M. BCAB currently screens at market cap $5.9M.
Use this BCAB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCAB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCAB SEC filings page. Lician reads the product cache first so this HTML stays unique to Bioatla Inc even when a live quote feed is slow.
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BCAB Key Statistics
Market Cap
$5.89M
Volume
55,175
Previous Close
$3.28
Day Range
$3.12 – $3.47
P/B Ratio
2.68
EPS
-$1.44
Revenue
$0.00
Net Income
-$69.78M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
41
BCAB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $300.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.78M | -$123.46M | -$106.48M | -$95.40M |
| EPS (Diluted) | -$1.44 | -$2.58 | -$2.74 | -$2.76 |
Total Assets
$52.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$49.05M
Operating Cash Flow
-$71.94M
Free Cash Flow
$0.00
Bioatla Inc Company Information
- Co-Founder, CEO & Chairman
- Jay M. Short Ph.D.
- Headquarters
- 11085 Torreyana Road, San Diego, CA, United States, 92121
- Website
- www.bioatla.com
- Phone
- 858 558 0708
- IPO / Founded
- 2020-12-16
- Sector
- Healthcare
- Industry
- Biotechnology